➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Colorcon
Merck
Mallinckrodt
Moodys
McKesson
Baxter

Last Updated: October 22, 2020

DrugPatentWatch Database Preview

Details for Patent: RE41956

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which drugs does patent RE41956 protect, and when does it expire?

Patent RE41956 protects VICTOZA and is included in one NDA.

Protection for VICTOZA has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has thirty-three patent family members in twenty countries.

Summary for Patent: RE41956
Title:Dose setting limiter
Abstract: A limiting mechanism which prevents the setting of a dose, which exceeds the amount of liquid left in a cartridge of an injection device, is disclosed. The injection device is the type where a dose is set by rotating a dose setting member relative to a driver and away from a fixed stop in the injection device. The dose setting member interfaces the driver such that the dose setting member can be rotated in one direction without rotating the driver. The dose is injected by rotating back the dose setting member which during the backward rotation carries the driver with it. Rotating the driver causes the piston rod to move forward inside the cartridge and expel some of the liquid contained in the cartridge. The driver is provided with a track having a length which is related to the total amount of liquid in the cartridge and which track is engaged by a track follower coupled to the dose setting member to follow rotation of this dose setting member. Each time a dose is set and injected, the track follower moves further into the track. When the track follower reaches the end of the track the dose setting member can not be rotated further, and a dose larger than the remaining liquid in the cartridge cannot be set.
Inventor(s): Klitgaard; Peter Christian (Glostrup, DK), Hansen; Steffen (Hillerod, DK), Radmer; Bo (Hillerod, DK), Moller; Claus Schmidt (Fredensborg, DK)
Assignee: Novo Nordisk A/S (Bagsvaerd, DK)
Application Number:11/122,211
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent RE41956
Patent Claim Types:
see list of patent claims
Use; Device; Delivery;

Drugs Protected by US Patent RE41956

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Novo Nordisk Inc VICTOZA liraglutide recombinant SOLUTION;SUBCUTANEOUS 022341-001 Jan 25, 2010 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: RE41956

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Denmark1999 01309Sep 16, 1999

International Family Members for US Patent RE41956

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 299728   Start Trial
Austria 452669   Start Trial
Australia 6820500   Start Trial
Australia 778714   Start Trial
Brazil 0014030   Start Trial
Canada 2383078   Start Trial
China 1183975   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Johnson and Johnson
Mallinckrodt
Colorcon
Harvard Business School
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.